<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3389">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062787</url>
  </required_header>
  <id_info>
    <org_study_id>CIN-401</org_study_id>
    <nct_id>NCT03062787</nct_id>
  </id_info>
  <brief_title>Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee</brief_title>
  <acronym>EEFFEK</acronym>
  <official_title>Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee (EEFFEK Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmascience Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmascience Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a post-license, multicenter, randomized, single blind, controlled study comparing a
      single injection of Cingal® (study arm) with a single injection of Monovisc® (control arm).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the local pain reduction after a single injection of Cingal® or Monovisc® over a 6 weeks period in patients with osteoarthritis of the knee assessed with the Western Ontario and McMaster Universities Arthritis Index (WOMAC)</measure>
    <time_frame>6 weeks post injection</time_frame>
    <description>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the maximum pain reduction by treatment arm</measure>
    <time_frame>6 weeks post injection</time_frame>
    <description>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the time to maximum pain reduction by treatment arm</measure>
    <time_frame>6 weeks post injection</time_frame>
    <description>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stiffness and physical function</measure>
    <time_frame>6 weeks post injection</time_frame>
    <description>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall change of WOMAC score</measure>
    <time_frame>6 weeks post injection</time_frame>
    <description>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum WOMAC score reduction</measure>
    <time_frame>6 weeks post injection</time_frame>
    <description>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Cingal®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monovisc®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cingal® (Sodium hyaluronate with Triamcinolone Hexacetonide)</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Cingal®</arm_group_label>
    <other_name>Cingal®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monovisc® (Sodium hyaluronate)</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Monovisc®</arm_group_label>
    <other_name>Monovisc®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of age

          -  Diagnosed with osteoarthritis of the knee

          -  Candidate for an intra-articular injection (single joint, unilateral) of Monovisc® or
             Cingal® as part of their routine clinical care and in accordance with the locally
             approved label

        Exclusion Criteria:

          -  Previous intra-articular injection within the last 6 months from enrolment

          -  Known hypersensitivity to cortico-steroids, hyaluronic acid or any component of
             Cingal® or Monovisc®

          -  Infectious, traumatic or neoplasic component of knee pathology

          -  Surgery of the knee within the last 6 months or scheduled surgery in the next two
             months from enrolment

          -  Patients with impaired cardio-renal function, endocrine, or other diseases or
             conditions that use of corticosteroid is warned.

          -  Patients with known bleeding disorders

          -  Patient currently treated with oral steroids or opioids

          -  Patients that, in the investigators' opinion, are unlikely to comply with protocol

          -  Pregnant or nursing women or women who suspect they might be pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohit Bhandari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genevieve Lehoux</last_name>
    <email>glehoux@pharmascience.com</email>
  </overall_contact>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>February 13, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
